Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Jul 13, 2026
Why Is AXT, Inc. (AXTI) Stock Down -15.12% Today?

Why Is AXT, Inc. (AXTI) Stock Down -15.12% Today?

Key Takeaways

  • AXTI shares plunged 15.12% in Monday's trading session, falling to $48.56 from a previous close of $57.21, extending a brutal multi-week selloff.
  • Broad semiconductor and AI infrastructure selloff is the primary catalyst, as mounting concerns over AI capital expenditure sustainability trigger a sector-wide reassessment.
  • Profit-taking and valuation compression continue to punish the stock, which has now fallen roughly 66% from its 52-week high of $143.16 reached just weeks ago.
  • Insider selling and regulatory uncertainty — including the withdrawal of subsidiary Tongmei's Shanghai IPO application — are compounding negative sentiment.
  • Technical breakdown below all major moving averages leaves the stock searching for a durable floor, with traders watching the $40–$45 zone as the next potential support area.

Opening Summary

AXTI, the stock of AXT, Inc. — a Fremont, California-based global manufacturer of compound semiconductor substrates including indium phosphide (InP), gallium arsenide (GaAs), and germanium (Ge) wafers used in AI data center optics, 5G infrastructure, and advanced optoelectronic devices — tumbled 15.12% in Monday's trading session. The shares, which closed the prior session on Friday at $57.21, fell to $48.56 in intraday trading, marking one of the steepest single-day percentage declines during an already punishing multi-week drawdown. Markets attributed the selloff primarily to a broad rotation out of high-valuation AI infrastructure names, intensifying concerns about the sustainability of AI capital expenditure, and ongoing pressure from insider selling and regulatory developments.

AI Capex Fears Trigger Broad Semiconductor Selloff

The most immediate driver of Monday's decline is a sector-wide rout in semiconductor and AI-linked names, as investors increasingly question whether the massive capital expenditure cycle that has powered AI infrastructure stocks can be sustained. Reports and analyst commentary questioning the durability of hyperscaler spending on AI data center buildouts have rippled through the supply chain, hitting upstream materials suppliers like AXT particularly hard. The stock, which had already fallen sharply from its June peak near $111, accelerated its descent as the broader semiconductor complex faced a synchronized correction. With AXTI trading at extreme valuation multiples relative to its current earnings power, the stock has been acutely vulnerable to any shift in sentiment around the AI spending narrative that fueled its parabolic rally.

Profit-Taking and Valuation Compression Intensify

Monday's plunge represents the latest leg of a valuation reassessment that has erased roughly two-thirds of AXTI's market value from its 52-week high of $143.16. The stock entered 2026 trading below $2 per share and subsequently delivered a year-to-date gain exceeding 2,500% at its peak, driven by enthusiasm for its indium phosphide substrates — a critical material for high-speed optical interconnects inside AI data centers. That rally pushed the company's market capitalization to approximately $9 billion despite a negative trailing P/E ratio and a net margin of -14.69%. Even after the current selloff, the stock trades at a price-to-sales ratio dramatically above the semiconductor industry average, leaving it exposed to further compression if growth expectations are recalibrated downward. Wall Street's consensus price target sits at roughly $43.80, with individual analyst targets ranging from $21.00 to $125.00, reflecting deep disagreement about the company's intrinsic value.

Insider Selling and Tongmei IPO Withdrawal Add Pressure

Compounding the technical and sector-driven selling, a pattern of heavy insider disposals has weighed on investor confidence. CEO Morris Young has sold over $37 million in company stock in recent months, while CFO Gary Fischer and multiple directors have also executed significant sales, with zero insider purchases recorded over the past six months. While insider selling does not inherently signal deteriorating fundamentals, the clustering of large sales near the stock's peak has been interpreted by the market as a tacit signal that those closest to the company viewed the valuation as stretched.

Adding a fresh layer of uncertainty, AXT disclosed in an SEC filing on July 8 that its majority-controlled subsidiary, Beijing Tongmei Xtal Technology, has withdrawn its long-pending IPO application on the Shanghai STAR Market and will instead pursue a listing on the Hong Kong Stock Exchange. The withdrawal triggers redemption rights for eleven private equity funds that invested approximately RMB 324 million (roughly $49 million) in Tongmei, each of which now has the right to demand repayment at the original investment amount. While the company stated it has sufficient funds to cover any redemptions, the shift introduces near-term liquidity questions and refocuses attention on the regulatory and geopolitical complexities of AXT's China-based manufacturing operations.

Market Context and Trading Activity

Monday's selloff occurred against a backdrop of broader market caution, with major indices under pressure and the semiconductor sector facing a deleveraging event that has swept through both large-cap and small-cap names. AXTI has now decisively broken below its 50-day moving average of approximately $95 and its 200-day moving average near $58, leaving the stock in a technically bearish posture with no nearby moving-average support. The 14-day Relative Strength Index (RSI) has plunged into oversold territory below 31, a level that can sometimes precede short-term bounces but has thus far failed to produce a durable reversal during this downtrend. The stock's 52-week range of $1.85 to $143.16 underscores the extraordinary volatility that has characterized AXTI throughout 2026, and the current price sits roughly 66% below the all-time high.

Elevated short interest — reported at approximately 11.86% of the float in late May — adds a combustible element to the price action. While high short interest can fuel sharp upside reversals if positive catalysts emerge, sustained downward momentum can also embolden short sellers, creating a self-reinforcing cycle that amplifies daily swings.

Trending AI Robots

In volatile market environments like the one currently affecting AXTI, traders often turn to automated strategies to navigate rapid sentiment shifts. Tickeron's Trending AI Robots page showcases a curated selection of the platform's top-performing AI trading bots, drawn from a universe of hundreds of bots that trade thousands of tickers across diverse strategies and timeframes. Only the strongest performers under prevailing market conditions are featured in this dynamically updated section, with each bot displaying transparent performance metrics, traded symbols, and strategy parameters. For traders seeking to complement their own analysis with data-driven, algorithmically generated signals, exploring the Trending AI Robots page offers a window into which automated approaches are currently demonstrating the most consistent results.

What Comes Next for AXTI

The immediate watchpoint for AXTI is whether the stock can find a durable floor after its precipitous decline. Key support levels to monitor include the $45 zone and the $40 round-number level, which corresponds to a congestion area from March. On the upside, any meaningful recovery would need to reclaim the $62–$65 breakdown zone that served as support in late June and early July.

The company's second-quarter earnings report, scheduled for July 30, represents the next major catalyst. Management guided for a return to GAAP profitability in Q2, and investors will scrutinize whether the company can deliver on that promise while providing updated commentary on its $100 million-plus indium phosphide backlog. Progress on export permit approvals from Chinese authorities remains the single most significant operational variable, as faster-than-expected approvals would unlock substantial revenue potential from the existing backlog.

Broader sector dynamics will also play a decisive role. If the current rotation out of high-valuation AI infrastructure names proves temporary, AXTI could find support from the same thematic tailwinds that powered its rally. If the reassessment deepens, the stock's rich valuation and negative earnings base leave it exposed to further downside. The resolution of the Tongmei redemption situation and any updates on the Hong Kong listing timeline will be closely watched for signals about the company's capital position and strategic direction.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: AXTI

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


AXTI in upward trend: price rose above 50-day moving average on August 06, 2026

AXTI moved above its 50-day moving average on August 06, 2026 date and that indicates a change from a downward trend to an upward trend. In of 50 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 30, 2026. You may want to consider a long position or call options on AXTI as a result. In of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for AXTI just turned positive on July 21, 2026. Looking at past instances where AXTI's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where AXTI advanced for three days, in of 277 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for AXTI moved out of overbought territory on August 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXTI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

AXTI broke above its upper Bollinger Band on August 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for AXTI entered a downward trend on August 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AXTI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 63, placing this stock slightly worse than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.814) is normal, around the industry mean (8.640). AXTI's P/E Ratio (2617.333) is considerably higher than the industry average of (168.044). AXTI's Projected Growth (PEG Ratio) (0.000) is very low in comparison to the industry average of (1.601). AXTI has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.006). P/S Ratio (32.468) is also within normal values, averaging (37.998).

Notable companies

The most notable companies in this group are Applied Materials (NASDAQ:AMAT), Lam Research Corp (NASDAQ:LRCX), KLA Corporation (NASDAQ:KLAC), Teradyne (NASDAQ:TER), Ambarella (NASDAQ:AMBA).

Industry description

The electronic production equipment industry makes equipment used to produce semiconductors. Such equipment includes wafer fabrication, plasma etching and photo-resist processing equipment. The industry also makes chemical vapor deposition processing systems and photomasks, which are high-purity quartz plates that contain patterns to define integrated circuits layouts. Applied Materials, Inc., Lam Research Corporation, and KLA-Tencor Corporation are examples of electronic production equipment manufacturing companies.

Market Cap

The average market capitalization across the Electronic Production Equipment Industry is 65.37B. The market cap for tickers in the group ranges from 555.66K to 689.17B. ASML holds the highest valuation in this group at 689.17B. The lowest valued company is AVSR at 555.66K.

High and low price notable news

The average weekly price growth across all stocks in the Electronic Production Equipment Industry was 6%. For the same Industry, the average monthly price growth was 5%, and the average quarterly price growth was 46%. AEHR experienced the highest price growth at 31%, while SMTK experienced the biggest fall at -23%.

Volume

The average weekly volume growth across all stocks in the Electronic Production Equipment Industry was -53%. For the same stocks of the Industry, the average monthly volume growth was -20% and the average quarterly volume growth was -62%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 64
P/E Growth Rating: 33
Price Growth Rating: 45
SMR Rating: 74
Profit Risk Rating: 62
Seasonality Score: -23 (-100 ... +100)
View a ticker or compare two or three
AXTI
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a manufactures of high-performance compound semiconductor substrates

Industry ElectronicProductionEquipment

Profile
Details
Industry
Electronic Production Equipment
Address
4281 Technology Drive
Phone
+1 510 438-4700
Employees
1075
Web
http://www.axt.com
Interact to see
Advertisement
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.